Hyoscine Hydrobromide


Antimuscarinics/anticholinergics such as hyoscine hydrobromide, atropine, glycopyrronium/glycopyrrolate, hyoscine butyl bromide are used primarily as smooth muscle antispasmodics and antisecretory agents. They are used in palliative care for intestinal colic, genitorurinary colic, inoperable bowel obstruction with colic and respiratory secretions at end of life. Hyoscine hydrobromide and glycopyrronium/glycopyrrolate are less likely to cross the blood-brain barrier as they are not as lipid-soluble, thereby causing less central side-effects (e.g. delirium).
Effective in reducing respiratory secretions at end of life in about ½ to ⅓ of patients.

Onset of action: < 10 minutes SC/IM/IV
Plasma ½ life: 5-6 h


  • 0.4 mg as a single dose SC
  • If effective, continue using 0.3-0.6 mg q4h SC
  • 1 year-12 years: 10 mcg/kg SC/IV as single dose; 20-60 mcg/kg over 24 hours in SC or IV infusion


  • Blurred vision
  • Cardiovascular effects
  • Dry mouth
  • Constipation
  • Heartburn
  • Urinary retention
  • Delirium


  • Avoid concurrent use with prokinetics as antimuscarinics will block the action of agents such as metoclopramide
  • Glaucoma may be precipitated in patients at risk


This information is drawn from a number of sources (see below). The reader is encouraged to access these and other relevant literature for more detail. As always, sound clinical judgment should be used in individual clinical cases. In particular, it should be remembered that there may be significant variation in the pharmokinetics of a drug resulting from a number of factors, including the individual patient’s metabolism/disease status and how the medication has been formulated.


  1. Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman’s: the pharmacological basis of therapeutics. 11th ed. McGraw-Hill Professional; 2006.
  2. Twycross R, Wilcock A. Palliative care formulary. 3rd ed. Radcliffe Medical Press Ltd; 2008.
  3. Repchinsky C, editor. Compendium of pharmaceuticals and specialties (CPS): the Canadian drug reference for health professionals. 44th ed. Canadian Pharmacists Association; 2009.
  4. Goldman A, Hain R, Liben S. Oxford textbook of palliative care for children. 1st ed. Oxford University Press; 2006.

Back to Malignant Bowel Obstruction, Respiratory Secretions at the End of Life

Unless otherwise stated, the content of this page is licensed under Creative Commons Attribution-ShareAlike 3.0 License

Subscription expired — please renew

Pro account upgrade has expired for this site and the site is now locked. If you are the master administrator for this site, please renew your subscription or delete your outstanding sites or stored files, so that your account fits in the free plan.